Compare HDSN & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HDSN | QTTB |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.0M | 265.2M |
| IPO Year | 1996 | 2018 |
| Metric | HDSN | QTTB |
|---|---|---|
| Price | $4.33 | $8.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $6.44 | ★ $39.67 |
| AVG Volume (30 Days) | 546.4K | ★ 551.6K |
| Earning Date | 10-28-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $237,118,000.00 | $53,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.68 | $150.00 |
| P/E Ratio | $35.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.10 | $1.91 |
| 52 Week High | $8.79 | $23.57 |
| Indicator | HDSN | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 26.24 | 49.67 |
| Support Level | N/A | $7.45 |
| Resistance Level | $6.47 | $9.16 |
| Average True Range (ATR) | 0.18 | 0.49 |
| MACD | -0.11 | 0.22 |
| Stochastic Oscillator | 14.82 | 82.65 |
Hudson Technologies Inc is a refrigerant services company providing solutions to recurring challenges within the refrigeration industry. The company delivers environmentally sustainable offerings, covering the sale of refrigerant gases, recovery, reclamation, and reuse, as well as improving equipment performance through energy efficiency services, emergency air conditioning and refrigeration system repairs, refrigerant disposal, and carbon credit trading. It operates through one reportable segment. Its products and services are used in commercial air conditioning, industrial processing, and refrigeration systems, and include refrigerant and industrial gas sales, refrigerant management services (mainly reclamation of refrigerants), and RefrigerantSide services performed at customer sites.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).